Promis Neurosciences (PMN) Competitors $0.77 0.00 (-0.60%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.76 -0.01 (-0.72%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. CTNM, LIMN, THTX, LYEL, IKT, TNYA, NKTX, CGEN, IOBT, and GNLXShould you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include Contineum Therapeutics (CTNM), Liminatus Pharma (LIMN), Theratechnologies (THTX), Lyell Immunopharma (LYEL), Inhibikase Therapeutics (IKT), Tenaya Therapeutics (TNYA), Nkarta (NKTX), Compugen (CGEN), IO Biotech (IOBT), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Promis Neurosciences vs. Its Competitors Contineum Therapeutics Liminatus Pharma Theratechnologies Lyell Immunopharma Inhibikase Therapeutics Tenaya Therapeutics Nkarta Compugen IO Biotech Genelux Contineum Therapeutics (NASDAQ:CTNM) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Do institutionals & insiders believe in CTNM or PMN? 50.1% of Promis Neurosciences shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, CTNM or PMN? Promis Neurosciences has lower revenue, but higher earnings than Contineum Therapeutics. Promis Neurosciences is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M3.08-$42.26M-$1.97-3.03Promis NeurosciencesN/AN/A$2.78M-$0.05-15.33 Does the media refer more to CTNM or PMN? In the previous week, Promis Neurosciences had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 4 mentions for Promis Neurosciences and 1 mentions for Contineum Therapeutics. Promis Neurosciences' average media sentiment score of 0.71 beat Contineum Therapeutics' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CTNM or PMN? Contineum Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Do analysts prefer CTNM or PMN? Contineum Therapeutics currently has a consensus price target of $22.50, indicating a potential upside of 277.52%. Promis Neurosciences has a consensus price target of $4.33, indicating a potential upside of 465.34%. Given Promis Neurosciences' higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CTNM or PMN more profitable? Contineum Therapeutics' return on equity of -24.59% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -24.59% -23.49% Promis Neurosciences N/A -186.19%-98.56% SummaryContineum Therapeutics beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks. Get Promis Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.21M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-15.3317.6228.6723.80Price / SalesN/A269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book1.538.508.275.55Net Income$2.78M-$55.06M$3.24B$259.03M7 Day Performance-22.30%-3.98%-3.63%-4.56%1 Month Performance71.09%9.59%4.40%4.49%1 Year Performance-42.37%6.72%25.97%18.05% Promis Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNPromis Neurosciences2.3666 of 5 stars$0.77-0.6%$4.33+465.3%-46.8%$25.21MN/A-15.335Upcoming EarningsShort Interest ↑Gap DownCTNMContineum Therapeutics2.4751 of 5 stars$5.18-8.3%$22.50+334.4%-69.4%$146.17M$50M-2.6331News CoverageGap DownHigh Trading VolumeLIMNLiminatus PharmaN/A$5.78+3.6%N/AN/A$145.16MN/A0.00N/AGap DownHigh Trading VolumeTHTXTheratechnologiesN/A$3.15+0.3%N/A+124.1%$144.38M$85.87M-16.58140LYELLyell Immunopharma2.9933 of 5 stars$10.28+8.3%$15.00+45.9%-63.3%$140.53M$60K-0.41270Upcoming EarningsGap DownIKTInhibikase Therapeutics2.0623 of 5 stars$1.93+2.7%$6.50+236.8%+10.9%$139.76MN/A-0.726TNYATenaya Therapeutics3.6584 of 5 stars$0.85-0.7%$6.25+634.7%-78.9%$139.34MN/A-0.73110News CoverageGap UpNKTXNkarta2.416 of 5 stars$2.08+8.3%$14.33+589.1%-66.9%$136.24MN/A-1.38140News CoveragePositive NewsCGENCompugen1.9957 of 5 stars$1.55+2.6%$4.00+158.1%-18.7%$134.75M$27.86M-9.6970Upcoming EarningsIOBTIO Biotech3.1849 of 5 stars$1.95-3.5%$9.33+378.6%+74.8%$133.08MN/A-1.3130Short Interest ↑GNLXGenelux1.7478 of 5 stars$3.30-6.0%$17.75+437.9%+79.1%$132.54M$10K-3.7510Positive News Related Companies and Tools Related Companies Contineum Therapeutics Alternatives Liminatus Pharma Alternatives Theratechnologies Alternatives Lyell Immunopharma Alternatives Inhibikase Therapeutics Alternatives Tenaya Therapeutics Alternatives Nkarta Alternatives Compugen Alternatives IO Biotech Alternatives Genelux Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMN Stock Alerts